Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001610618-25-000041
Filing Date
2025-04-25
Accepted
2025-04-25 16:16:28
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A cdtxdefa14a04-25x2025.htm DEFA14A 12948
2 GRAPHIC cdtx_noticexpagex1.jpg GRAPHIC 3118802
3 GRAPHIC cdtx_noticexpagex2.jpg GRAPHIC 4297926
  Complete submission text file 0001610618-25-000041.txt   10212116
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36912 | Film No.: 25874296
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)